secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0000950170-22-026017
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax appoints Steve Sabus as CCO; base $495K, option for 220K shares
----------------------------------------------------------------------

- Steve Sabus joins as Chief Commercial Officer effective December 5, 2022.
- Annual base salary of $495,000 with target bonus of 40% and option grant for 220,000 shares.
- Sabus previously CCO at Turning Point Therapeutics and 15-year Astellas veteran.
- Role focuses on commercial strategy for potential 2024 launches of revumenib and axatilimab.
- Severance includes 9-month base salary on termination w/o cause or good reason; 12-month + full vesting on change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/0000950170-22-026017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/sndx-20221201.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer